ARGX News and Press, argenx SE From 06/19/24

2024-06-19 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commi...

2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...

2024-06-12 10:29:57 ET Summary Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients a...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-09 20:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

June 4, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the ...

2024-05-28 17:30:05 ET Barclays analyst issues EQUAL-WEIGHT recommendation for ARGX on May 28, 2024 03:39PM ET. The previous analyst recommendation was Equal-Weight. ARGX was trading at $366.34 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-09 16:39:11 ET argenx SE (ARGX) Q1 2024 Earnings Conference Call May 09, 2024, 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer K...